Detalhe da pesquisa
1.
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
J Am Acad Dermatol
; 84(2): 398-407, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961255
2.
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
J Am Acad Dermatol
; 82(2): 519-522, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563641
3.
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
Clin Cancer Res
; 20(23): 5927-36, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25231400